ChemoMetec

the NucleoCounter line (NC-200, NC-203, NC-3000) and the newer XcytoMatic platform use a closed reagent-cassette design that limits user contact with the sample, positioned for consistent counting in regulated manufacturing environments.

Country
Denmark
Ticker
CPH:CHEMM
CPH:CHEMM Commercial
Coverage
CNEUUS
analytics-pat✓✓✓
Regulatorsfdaemanmpa

Verifiable facts

FactValueSource
Founded1997companydata.dk · investor.chemometec.com · globenewswire.com
HeadquartersAllerød, Denmarkinvestor.chemometec.com
Headcount170 employees (as of 2025-06-30)companydata.dk · investor.chemometec.com · marketscreener.com
RevenueDKK 495.6 million (FY 2024/25)companydata.dk · investor.chemometec.com · globenewswire.com
Production siteAllerød, Denmark (head office and automated production facilities)investor.chemometec.com
Regulatory approvalInstruments (NC-200, NC-203, XcytoMatic) are 21 CFR Part 11/GMP-readychemometec.com · investor.chemometec.com

Independent sources: companydata.dk · globenewswire.com · marketscreener.com

Technologies
NameClusterRisk
Cell counters and viability systemsanalytics-patLow→

Compiled by BIOECON from primary sources.

Compliance Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.